So far as our Directors are aware, the following persons will, immediately prior to and following the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares, have interests or short positions in our Shares or underlying Shares which would be required to be disclosed to us under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any types of our issued voting shares of any member of our Group:

LONG POSITIONS IN SHARES OF OUR COMPANY

Name of Shareholder	Nature of interest	Shares held as of the date of this document and immediately prior to the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			Shares held immediately following the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			
		Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares	Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares	Percentage of shareholding in the total issued share capital
				(approx.)			(approx.)	(approx.)
Hangzhou Quanyi ⁽³⁾	Beneficial owner	[REDACTED] Shares	40,000,000 (L)	19.05%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Xinfu Tongxin ⁽⁴⁾	Beneficial owner	[REDACTED] Shares	15,550,000 (L)	7.40%	n Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Mr. Qiu ⁽³⁾⁽⁴⁾⁽⁵⁾⁽⁶⁾	Beneficial owner Interest in controlled corporations	[REDACTED] Shares	70,550,000 (L)	33.59%	[REDACTED] Shares H Shares	[REDACTED] (L) [REDACTED] (L)	[REDACTED]%	[REDACTED]%
Ms. Xu Qiu (許秋) ⁽⁷⁾	Interest of spouse	[REDACTED] Shares	70,550,000 (L)	33.59%	[REDACTED] Shares H Shares	[REDACTED] (L) [REDACTED] (L)	[REDACTED]%	[REDACTED]%
Mr. Yu ⁽³⁾	Interest in a controlled corporation	[REDACTED] Shares	40,000,000 (L)	19.05%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Ms. Zhu Jing	Interest of	[REDACTED]	40,000,000	19.05%	H Shares	[REDACTED]	[REDACTED]%	[REDACTED]%
(朱靜) ⁽⁸⁾ Zhongmei Huadong ⁽⁹⁾	spouse Beneficial owner	Shares [REDACTED] Shares	(L) 35,900,000 (L)	17.09%	H Shares	(L) [REDACTED] (L)	[REDACTED]%	[REDACTED]%
Huadong Medicine ⁽⁹⁾	Interest in a controlled corporation	[REDACTED] Shares	35,900,000 (L)	17.09%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%

Name of Shareholder	Nature of interest	Shares held as of the date of this document and immediately prior to the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			Shares held immediately following the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			
		Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares	Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares	Percentage of shareholding in the total issued share capital
				(approx.)			(approx.)	(approx.)
China Grand Enterprises Incorporation (中國遠大集團有限責任公司) ("China Grand") ⁽⁹⁾	Interest in controlled corporations	[REDACTED] Shares	35,900,000 (L)	17.09%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Beijing Grand Huachuang Investment Co., Ltd. (北京遠大華 創投資有限公司) ("Beijing Grand") ⁽⁹⁾	Interest in controlled corporations	[REDACTED] Shares	35,900,000 (L)	17.09%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Mr. Hu Kaijun (胡凱軍) ⁽⁹⁾	Interest in controlled corporations	[REDACTED] Shares	35,900,000 (L)	17.09%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Hongtai Health ⁽¹⁰⁾	Beneficial owner	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Hongtai Aplus ⁽¹⁰⁾	Interest in controlled corporations	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Qingdao Xinchen Sci-Tech Innovation Industrial Co., Ltd (青島鑫宸科 創實業有限公司) ("Qingdao Xinchen") ⁽¹⁰⁾	Interest in controlled corporations	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Mr. Sheng Xitai (盛希泰) ⁽¹⁰⁾	Interest in controlled corporations	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%

Name of Shareholder	Nature of interest	Shares held as of the date of this document and immediately prior to the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			Shares held immediately following the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			
		Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares	Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares	Percentage of shareholding in the total issued share capital
				(approx.)			(approx.)	(approx.)
Zijin Trust ⁽¹⁰⁾	Interest in controlled corporations	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Nanjing Zijin Investment Group Co., Ltd. (南京紫 金投資集團有限責 任公司) ("Nanjing Zijin") ⁽¹⁰⁾	Interest in controlled corporations	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Nanjing State- owned Assets Investment & Management Holding (Group) Co., Ltd. (南京市 國有資產投資管理 控股(集團)有限責 任公司) ("Nanjing Assets") ⁽¹⁰⁾	Interest in controlled corporations	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Taizhou Huacheng ⁽¹⁰⁾	Interest in controlled corporations	[REDACTED] Shares	18,750,000 (L)	8.93%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Taizhou Jianxin ⁽¹¹⁾	Beneficial owner	[REDACTED] Shares	7,500,000 (L)	3.57%	[REDACTED] Shares H Shares	[REDACTED] (L) [REDACTED]	[REDACTED]% [REDACTED]%	[REDACTED]%
Taizhou Huayin ⁽¹¹⁾⁽¹²⁾	Interest in controlled corporations	[REDACTED] Shares	15,000,000 (L)	7.14%	[REDACTED] Shares	(L) [REDACTED] (L)	[REDACTED]%	[REDACTED]%
	1				H Shares	[REDACTED] (L)	[REDACTED]%	
Taizhou Medical High-tech ⁽¹¹⁾⁽¹²⁾	Interest in controlled corporations	[REDACTED] Shares	15,000,000 (L)	7.14%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
	•				H Shares	[REDACTED] (L)	[REDACTED]%	

Name of Shareholder	Nature of interest	Shares held as of the date of this document and immediately prior to the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			Shares held immediately following the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			
				Percentage of shareholding in the			Percentage of shareholding in the	Percentage of shareholding in the total
		Type of Shares ⁽²⁾	Number	relevant type of Shares	Type of Shares ⁽²⁾	Number	relevant type of Shares	issued share capital
				(approx.)			(approx.)	(approx.)
Taizhou Medicine ⁽¹⁰⁾⁽¹¹⁾⁽¹²⁾	Interest in controlled corporations	[REDACTED] Shares	33,750,000 (L)	16.07%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
	corporations				H Shares	[REDACTED] (L)	[REDACTED]%	
Matrix China Management VI, L.P. (13)	Interest in controlled corporations	[REDACTED] Shares	10,920,000 (L)	5.20%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Matrix China VI GP GP, Ltd. (13)	Interest in controlled corporations	[REDACTED] Shares	10,920,000 (L)	5.20%	H Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Jiaxing Jiquan ⁽¹⁴⁾	Beneficial owner	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Shanghai Jincheng Equity Investment Fund Management Co., Ltd (上海晉 成股權投資基金管 理有限公司) ("Shanghai Jincheng") ⁽¹⁴⁾	Interest in controlled corporations	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Mr. Xiong Yongxiang (熊永祥) ⁽¹⁴⁾	Interest in controlled corporations	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Ms. Zheng Qing'ai (鄭青愛) ⁽¹⁴⁾	Interest in controlled corporations	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Shanghai Jincheng Enterprise Development Group Co., Ltd (上海晉成企業發 展集團有限公司) ("Shanghai Jincheng Group") ⁽¹⁴⁾	Interest in controlled corporations	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%

Name of Shareholder	Shares held as of the date of this document and immediately prior to the completion of the [REDACTED] Nature of interest into H Shares ⁽¹⁾				Shares held immediately following the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares ⁽¹⁾			
		Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares (approx.)	Type of Shares ⁽²⁾	Number	Percentage of shareholding in the relevant type of Shares (approx.)	Percentage of shareholding in the total issued share capital (approx.)
Jincheng (Shanghai) Industrial Co., Ltd (晉成(上海)實 業有限公司) ("Jincheng Industrial") ⁽¹⁴⁾	Interest in controlled corporations	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Mr. Gu Dongchen (顧棟臣) ⁽¹⁴⁾	Interest in controlled corporations	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%
Mr. Gu Zhiqiang (顧志強) ⁽¹⁴⁾	Interest in controlled corporations	[REDACTED] Shares	3,572,400 (L)	1.70%	[REDACTED] Shares	[REDACTED] (L)	[REDACTED]%	[REDACTED]%

Notes:

- (1) The letter "L" denotes the person's long position in our Shares.
- (2) [REDACTED] Shares and H Shares are regarded as two different types of Shares. For the avoidance of doubt, both [REDACTED] Shares and H Shares are ordinary Shares in the share capital of our Company, and are considered as one class of Shares.
- (3) Hangzhou Quanyi is owned as to 50% by Mr. Qiu and 50% by Mr. Yu Guo'an, both being its general partners acting in concert pursuant to the supplemental partnership agreement of Hangzhou Quanyi. For details, see "Relationship with Our Controlling Shareholders—Overview" in this document. By virtue of the SFO, each of Mr. Qiu and Mr. Yu Guo'an is deemed to be interested in the Shares held by Hangzhou Quanyi.
- (4) Mr. Qiu is the general partner who holds approximately 7.20% interest in Xinfu Tongxin. By virtue of the SFO, Mr. Qiu is deemed to be interested in the Shares held by Xinfu Tongxin.
- (5) Mr. Qiu is the general partner who holds approximately 45.71% interest in Shanghai Quanyou. Shanghai Quanyou holds 5,000,000 Shares, representing approximately 2.38% and [REDACTED]% of our Shares in issue immediately prior to and following the completion of the [REDACTED]. By virtue of the SFO, Mr. Qiu is deemed to be interested in the Shares held by Shanghai Quanyou.
- (6) Mr. Qiu directly holds 10,000,000 Shares, representing approximately 4.76% and [REDACTED]% of our Shares in issue immediately prior to and following the completion of the [REDACTED].
- (7) Ms. Xu Qiu is the spouse of Mr. Qiu. By virtue of the SFO, Ms. Xu Qiu is deemed to be interested in the Shares held by Mr. Qiu.

- (8) Ms. Zhu Jing is the spouse of Mr. Yu Guo'an. By virtue of the SFO, Ms. Zhu Jing is deemed to be interested in the Shares held by Mr. Yu Guo'an.
- (9) Zhongmei Huadong is wholly owned by Huadong Medicine. Huadong Medicine is owned as to approximately 41.66% by China Grand as its controlling shareholder. China Grand is owned as to approximately 92.97% by Beijing Grand, which is wholly owned by Mr. Hu Kaijun. By virtue of the SFO, each of Huadong Medicine, China Grand, Beijing Grand and Mr. Hu Kaijun is deemed to be interested in the Shares held by Zhongmei Huadong.
- (10) Hongtai Health is owned as to approximately 0.88% by Hongtai Aplus as its general partner, 55.07% by Taizhou Huacheng and 44.05% by Zijin Trust, both being its limited partners. Hongtai Aplus is wholly owned by Qingdao Xinchen, a company controlled by Mr. Sheng Xitai. Taizhou Huacheng is owned as to approximately 93.23% by Taizhou Medicine. Zijin Trust is owned as to approximately 50.67% by Nanjing Zijin, a company wholly owned by Nanjing Assets. By virtue of the SFO, each of Hongtai Aplus, Qingdao Xinchen, Mr. Sheng Xitai, Taizhou Huacheng, Taizhou Medicine, Zijin Trust, Nanjing Zijin and Nanjing Assets is deemed to be interested in the Shares held by Hongtai Health.
- (11) Taizhou Jianxin is an investment fund company managed by Taizhou Huaxin, a company owned as to approximately 91.25% by Taizhou Huayin. Taizhou Huayin is owned as to approximately 41.76% by Taizhou Medical High-tech, 31.50% by Taizhou Oriental (a company owned as to 90% by Taizhou Medicine), and 10.50% by Taizhou Huacheng (a company owned as to approximately 93.23% by Taizhou Medicine). Taizhou Jianxin holds 7,500,000 Shares, representing approximately 3.57% and [REDACTED]% of our Shares in issue immediately prior to and following the completion of the [REDACTED]. By virtue of the SFO, each of Taizhou Huaxin, Taizhou Huayin, Taizhou Medical High-tech and Taizhou Medicine is deemed to be interested in the Shares held by Taizhou Jianxin.
- (12) Rongjianda is an investment fund company managed by Rongjianda VC, which is owned as to 81% by Taizhou Huayin. Rongjianda is owned as to approximately 33.33% by Taizhou High-tech Industry Investment Development Co., Ltd. (泰州市高新產業投資有限公司) ("Taizhou High-tech"), 33.33% by Taizhou Huayin and 32.33% by Taizhou Huajian, a company wholly owned by Taizhou Huayin. Taizhou High-tech is a wholly owned subsidiary of Taizhou Financial Holding Group Co., Ltd. (泰州市金融控股集團有限公司) ("Taizhou Financial"), a company owned as to approximately 60.13% by Taizhou People's Municipal Government State-owned Assets Supervision and Administration Commission (泰州市人民政府國有資產監督管理委員會). Taizhou Huayin is owned as to approximately 41.76% by Taizhou Medical High-tech, 31.50% by Taizhou Oriental (a company owned as to 90% by Taizhou Medicine), and 10.50% by Taizhou Huacheng (a company owned as to approximately 93.23% by Taizhou Medicine). Rongjianda holds 7,500,000 Shares, representing approximately 3.57% and [REDACTED]% of our Shares in issue immediately prior to and following the completion of the [REDACTED]. By virtue of the SFO, each of Rongjianda VC, Taizhou High-tech, Taizhou Financial, Taizhou Huayin, Taizhou Medical High-tech and Taizhou Medicine is deemed to be interested in the Shares held by Rongjianda.
- (13) The general partner of Matrix Partners China VI, L.P. and Matrix Partners China VI-A, L.P. is Matrix China Management VI, L.P.. The general partner of Matrix China Management VI, L.P. is Matrix China VI GP GP, Ltd.. Matrix Partners China VI, L.P. and Matrix Partners China VI-A, L.P. in aggregate hold 10,920,000 Shares, representing approximately 5.20% and [REDACTED]% of our Shares in issue immediately prior to and following the completion of the [REDACTED]. By virtue of the SFO, each of Matrix China Management VI, L.P. and Matrix China VI GP GP, Ltd. is deemed to be interested in the Shares held by Matrix Partners China VI, L.P. and Matrix Partners China VI-A, L.P..
- (14) Jiaxing Jiquan is a limited partnership owned as to approximately 1.67% by Shanghai Jincheng as its general partner, 45% by Mr. Xiong Yongxiang and approximately 33.33% by Ms. Zheng Qing'ai, being two of its limited partners. Shanghai Jincheng is owned as to 90% by Shanghai Jincheng Group. Shanghai Jincheng Group is owned as to 99% by Jincheng Industrial, a company owned as to 50% by Mr. Gu Dongchen and 50% Mr. Gu Zhiqiang.

LONG POSITIONS IN EQUITY INTEREST OF MEMBERS OF OUR GROUP

			Equity	Equity
			interest held	interest held
			immediately	immediately
			prior to the	following the
Name of	Member of	Nature of	completion of	completion of
Shareholder	our Group	interest	the [REDACTED]	the [REDACTED]
			(approx.)	(approx.)
Taizhou Huacheng ⁽¹⁾	Cellularforce	Beneficial owner	34.00%	[REDACTED]%
Taizhou Medicine ⁽¹⁾	Cellularforce	Interest in controlled corporation	34.00%	[REDACTED]%

Note:

Except as disclosed above, our Directors are not aware of any person will, immediately prior to and following the completion of the [REDACTED] and conversion of [REDACTED] Shares into H Shares, have interests or short positions in any Shares or underlying Shares, which would be required to be disclosed to us under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly interested in 10% or more of the nominal value of any types of our issued voting shares of any member of our Group. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company.

⁽¹⁾ Taizhou Huacheng is owned as to approximately 93.23% by Taizhou Medicine. By virtue of the SFO, Taizhou Medicine is deemed to be interested in the equity interest held by Taizhou Huacheng.